| Document |
Document Title |
|
WO/2015/055602A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2015/055604A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R 4, R 5, R 6, R7, R 8, R 9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compoun...
|
|
WO/2015/051496A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated b...
|
|
WO/2015/051725A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated b...
|
|
WO/2015/049022A1 |
The invention relates to a heteroaryl compound according to formula (I) and to the use thereof in electronic devices.
|
|
WO/2015/043404A1 |
The present invention relates to a salt of (-)-huperzine-a, which is prepared from the reaction of huperzine-a and a corresponding acid. The huperzine-a salt is selected from huperzine-a hydrochloride, hydrobromide, sulfate, phosphate, n...
|
|
WO/2015/027058A2 |
Cycloalkyl amine compounds of Formula (I), wherein ring A is C3-C6 cycloalkyl, optionally substituted with one or more C1-C3 alkyl, and R5 is ORS2, in which RS2 is H or C1-C6 alkyl, or R5 and R6, together with the carbon atom to which th...
|
|
WO/2015/018176A1 |
Disclosed is the use of a compound as shown by formula (1) for a specific fluorescent probe of glucuronosyltransferase UGT1A1.
|
|
WO/2015/018177A1 |
Disclosed are a specific fluorescent probe molecule based on an albumin pseudo-esterase hydrolysis reaction and a use thereof, based on the characteristic pseudo-esterase activity of human serum albumin (HSA), i.e. HSA can catalyse the h...
|
|
WO/2015/020553A1 |
The present invention provides carbazole compounds of the formula (I), which can be used for treating microbial, protozoan, viral infections and cancer.
|
|
WO/2015/016155A1 |
This invention addresses the problem of providing the following: a photoelectric conversion material that excels in terms of vapor-deposition stability, and when made into a photoelectric conversion element, results in little in the way ...
|
|
WO/2015/011087A1 |
The invention relates to substituted oxopyridine derivatives of formula (I), in which n stands for the number 1 or 2, A stands for -N(R2)- or -CH2-, R1 stands for a group of formula (II), R3 and R4 stand for hydrogen, and R5 stands for a...
|
|
WO/2015/007129A1 |
The present invention relates to a method for preparing (-)-huperzine A. The method involves: allowing (±)- huperzine A mixture obtained from chemical synthesis and a chiral acid to form (±)-huperzine A chiral acid salt under suitable ...
|
|
WO/2015/001804A1 |
Provided is a non-ionic photoacid generator having high i-line photosensitivity, excellent heat-resistant stability, and excellent solubility in hydrophobic materials. The present invention is a non-ionic photoacid generator (A) that is ...
|
|
WO/2015/000546A1 |
The present invention relates to compounds having polycyclic structural units and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2014/206877A1 |
The compounds of formula (I), or its pharmaceutically acceptable salts, or any stereoisomer or mixture thereof, wherein: R1 and R1' are both H, or R1 and R1' are taken together forming a biradical of formula -CH2-C(R4)=CH-; R2 and R3 are...
|
|
WO/2014/209883A1 |
The present invention relates to the synthesis of polycyclic aromatic compounds. Compounds such as terrylene or quaterrylene may now be prepared in relatively high yield by reaction of naphthalene or perylene via Scholl-type coupling in ...
|
|
WO/2014/185751A1 |
The present invention relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the present invention, an organic electroluminescen...
|
|
WO/2014/180984A1 |
The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or chemoprevention of cancer hematological mal...
|
|
WO/2014/181788A1 |
The present invention provides: a novel α-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the α-substituted glycineamide derivative or a pharmacologically acce...
|
|
WO/2014/160671A1 |
Methods and fluorescent probes that detect the presence of diseased cells such as cancer. The fluorescent probes are cloaked, turn-on probes having the fluorescence reporter released only in the presence of enzymes typically over-express...
|
|
WO/2014/158654A1 |
Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well...
|
|
WO/2014/157152A1 |
The present invention addresses the problem of providing a photoelectric conversion element that excels in responsivity and shows high photoelectric conversion efficiency, a method for using the photoelectric conversion element, and an o...
|
|
WO/2014/149198A1 |
Disclosed herein is a compound for use in a composition applied to a blood vessel, wherein the compound softens and/or disrupts the crystalline matrix of calcified plaque. Methods of treatment comprising applying the disclosed compositio...
|
|
WO/2014/152737A1 |
Disclosed herein is a method for selectively modifying a substitutable carbon atom of an organic compound containing an amine, a sulfide, or an amine and a sulfide. The method makes use of the reactivity of amines and sulfides, which can...
|
|
WO/2014/150976A1 |
An improved process for obtaining at least one bis-benzyl isoquinoline alkaloid from botanical material involves contacting the botanical material with a supercritical fluid having as a major component one or more aliphatic hydrocarbon c...
|
|
WO/2014/140078A1 |
This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as ag...
|
|
WO/2014/140081A1 |
This invention relates to bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and their use in methods of treatment and/or prev...
|
|
WO/2014/131368A1 |
Provided are phenanthridine derivatives shown by general formula (I), pharmaceutical compositions comprising the derivatives, preparation methods therefor, and uses thereof for manufacturing medicines for the prophylaxis or treatment of ...
|
|
WO/2014/125410A1 |
The present invention provides N-substituted novel heterocyclic derivatives of formula (I) as protein kinase inhibitors, in which R1, R2 and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts the...
|
|
WO/2014/123238A1 |
Provided is an organic light-emitting device having high efficiency and improved driving durability performance. The organic light-emitting device includes a pair of electrodes and an organic compound layer placed between the pair of ele...
|
|
WO/2014/123239A1 |
Provided is a long-lifetime organic light-emitting element having a good device lifetime characteristic. The organic light-emitting device includes: a pair of electrodes; and an organic compound layer placed between the pair of electrode...
|
|
WO/2014/118618A1 |
The present invention is directed to Benzomorphan Analog compounds of the Formula I-ID as shown below, wherein R1, R2a, R2b, R3 and R4 are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and othe...
|
|
WO/2014/119636A1 |
Provided are: a novel compound which has an antiviral effect, in particular, HIV replication inhibitory activity; and a pharmaceutical product, in particular, an anti-HIV agent which contains the novel compound. A compound which is repre...
|
|
WO/2014/115853A1 |
The propellane derivatives represented by general formula (I) or pharmaceutically-acceptable acid addition salts thereof, or hydrates or solvates of said propellane derivatives and acid addition salts are used as analgesics, antidepressa...
|
|
WO/2014/112360A1 |
[Problem] To provide: an organic compound which has such characteristic properties that the organic compound can exhibit excellent hole injection/transport performance and an excellent electron stopping ability, is highly stable when for...
|
|
WO/2014/104386A1 |
Provided is an organic light-emitting element improved in luminous efficiency and lifetime. The organic light-emitting element includes a pair of electrodes and an organic compound layer placed between the pair of electrodes, in which th...
|
|
WO/2014/091020A1 |
The present invention refers to phenanthrene derivatives for use as medicaments, in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spin...
|
|
WO/2014/083785A1 |
[Problem] To provide an organic compound having excellent hole injection and transport capability, electron blocking capability, high stability in a thin-film state, and excellent heat resistance, as a material for a high-efficiency, dur...
|
|
WO/2014/084269A1 |
Provided are a compound having large absorption of light of a wavelength of 365 nm and a good acid-generation rate; and a photoacid generator, cationic polymerization initiator, resist composition, and cationically polymerizable composit...
|
|
WO/2014/073409A1 |
This aromatic imide compound having improved solubility and improved sensitivity toward visible light such as g-rays and h-rays is represented by formula (1) (In the formula: R1 represents a C1-7 haloalkyl group or haloaryl group; R2 rep...
|
|
WO/2014/072809A2 |
The present invention is directed to Benzomorphan Analog compounds of the Formula I", Formula IA", Formula IB", Formula IC", or Formula ID" as shown below; and related Formula I', Formula IA', Formula IB', Formula IC', or Formula ID'; Fo...
|
|
WO/2014/059232A2 |
The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, a...
|
|
WO/2014/055548A1 |
Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
|
|
WO/2014/048165A1 |
Disclosed is a compound as a potassium channel modulator, which is a compound of general formula (I) or a pharmaceutically acceptable salt thereof. Such compound can be used to prepare drugs for increasing the flow of ions in potassium c...
|
|
WO/2014/041125A1 |
The present invention relates to novel inhibitors of p21. These inhibitors are useful as therapeutic agents for promoting cell regeneration and in the treatment of cancer. Improvement of cell regeneration is particularly desirable in pat...
|
|
WO/2014/036502A2 |
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composi...
|
|
WO/2014/031750A1 |
Novel acenaphthylene imide-derived semiconductor materials, including small molecule compounds, polymers and oligomers. Also provided are methods for making the novel semiconductor materials and the use of the novel semiconducting materi...
|
|
WO/2014/024074A1 |
Compounds of general formula I, II, III and IV: Formula (I) wherein the variables have the meaning given in the description, and a process for the preparation of compounds of general formula I, II, III and IV are disclosed. The use of th...
|
|
WO/2014/019186A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated b...
|
